Phase 3 N=801 Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
Chronic Hand Eczema
Primary: Number of Treatment-emergent Adverse Events From Baseline up to Week 38 — 1238 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=442 Home Based Peer Support Program for Mothers With Low Breastfeeding Self-efficacy
Breastfeeding
Primary: Infant Feeding Status: Exclusive Breastfeeding — 46; 39 Participants
N/A N=963 Cancer Loyalty Card Study
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001
N/A N=167 Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)
Temporal Lobe Epilepsy
Primary: Incidence of Qualifying Adverse Events — 7.9 percentage of participants
N/A N=21 TMD Online Program for Pain Management
TMD/Orofacial Pain
Primary: Treatment Feasibility — 18 Participants — p=.05
N/A N=852 Communities Fighting COVID Return to School
COVID-19
Primary: Adherence to the Weekly COVID-19 Testing Schedule — 0.394; 0.352 proportion of scheduled tests completed
N/A N=142 Feasibility Study: Effect of Patient Decision Aids for Total Joint Replacement on Surgical Referrals
Osteoarthritis
Primary: Feasibility of Data Collection at Month 12 — 55; 48; 5; 9 Participants
N/A N=4 Dexterous Partial Hand Prosthesis Outcomes
Amputation · Amputation; Traumatic, Hand · Limb; Absence, Congenital, Upper
Primary: Jebsen-Taylor Small Common Objects Functional Test — 34.8; 26.1; 97.2; 62.1 Seconds
Phase 2 N=248 A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus · Chronic Kidney Diseases
Primary: The Primary Endpoint Was Percentage Change in UACR of Cotadutide at Different Dose Levels Compared to Placebo After 14 Weeks — -10.96; -40.47; -44.60; 4.60 Percentage…
Phase 2 N=44 Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
Type 1 Diabetes Mellitus
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period — 28; 13; 4; 1 Participants
Phase 2 N=10 ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection
Clostridium Difficile Infection
Primary: Segment 2A: Clinical Cure (CC) of Clostridioides Difficile Infection (CDI) Per Protocol (PP)/Modified Intent-to-Treat (mITT) Population — 10; 0 Participants
N/A N=75 Heart EXPAND Continued Access Protocol
Heart Transplant
Primary: Patient Survival at Day 30 Post-transplantation and Absence of Severe PGD (Left or Right Ventricle) in the First 24 Hours Post-transplantation — 72 Participants
Phase 3 N=75 Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Immune Thrombocytopenia
Primary: Durable Platelet Response — 15; 0 Participants — p=0.0077
N/A N=672 Patient-centered and Efficacious Advance Care Planning in Cancer: the PEACe Comparative Effectiveness Trial
Cancer · Advance Care Planning
Primary: Advance Care Planning Engagement — 4.08; 4.34 score on a scale — p=0.0014
N/A N=194 Rural Tailored COVID-19 Communication to Promote SARS-CoV-2 Antibody Testing in Saliva
SARS-CoV2 Infection
Primary: Number (Percentage) of Participants Requested to Participate in Home-based Saliva-based SARS-CoV-2 Antibody Testing. — 91; 88 Participants